Home Overview Press Room Blog Publications For Students about us
Search

What Kind of Bioethics Council Do We Need? / The Battle to Patent Your Genes

August 20th, 2009

If you are having difficulty viewing this email, read it on our web site
To ensure delivery, please add [email protected] to your address book or contacts.

Center For Genetics And Society
MONTHLY NEWS
August 20, 2009
arrow What Kind of Bioethics Council Do We Need?
arrow The Battle to Patent Your Genes
arrow Live Mice and Sperm - Both from Stem Cells - Create New Social and Ethical Challenges
arrow The Latest from Biopolitical Times
arrow Other News
You can also follow the Center on our webpage, blog, RSS, weekly newsletter, Facebook, Twitter, and YouTube.
What Kind of Bioethics Council Do We Need?
Science Tells Us What We Can Do; Values Tell Us What We Should

by Marcy Darnovsky, Science Progress

A new bioethics council must incorporate viewpoints from Americans of all walks of life, maintain an appropriate distance from both scientific and commercial interests, and build on the experience of other nations.

The Battle to Patent Your Genes:
The Meaning of the Myriad Case

by Marcy Darnovsky and Jesse Reynolds, The American Interest

A legal showdown looms over the patenting of human genes.
Live Mice and Sperm - Both from Stem Cells - Create New Social and Ethical Challenges
Public interest group calls for federal oversight of reproductive uses

[Press Statement]

Recent developments in cell reprogramming methods raise significant new ethical and social challenges.

The Latest from Biopolitical Times

The recession, sperm banks, and eugenics
by Jesse Reynolds
During the recession, more men are seeking to provide sperm in exchange for a hundred bucks.
Pfizer Settles Trovan Suit. Partially.

by Osagie Obasogie

There seems to have been at least a partial resolution in Nigeria’s lawsuit against Pfizer for running ethically questionable clinical trials during a meningitis epidemic.
Kiddie Gene Testing in China

by Osagie Obasogie

China has a longstanding reputation for identifying children’s talents at an early age in order to focus their training for future productivity. This effort may now be reaching new levels.
The new stem cell—and more—lobby
by Jesse Reynolds
Why is a new lobby for stem cell research and regenerative medicine needed?
Would you like them with a mouse?
by Pete Shanks
Japanese scientists report that mice have (almost) been fooled into making mammoth eggs.
23andMe Lite
by Jesse Reynolds
23andMe now offers a "lite" version of its scan for just a quarter of the normal price, but in exchange customers must provide personal medical information.

Other News

The Gene Hunt: Should Finders Be Keepers?
[Quotes CGS's Marcy Darnovsky]
by Lynne Peeples, Scientific American
A lawsuit filed against Myriad Genetics questions the ethics of gene patents.
New York OKs paying women who donate eggs for research
[Quotes CGS's Marcy Darnovsky]
by Kevin B. O'Reilly, American Medical News
Egg providers may get up to $10,000, an amount critics say could induce women to take unnecessary medical risks.
DNA Evidence Can Be Fabricated, Scientists Show
by Andrew Pollack, New York Times
With fabricated blood or saliva, “you can just engineer a crime scene,” said the lead author of a new study.
Cost of Decoding a Genome Is Lowered
by Nicholas Wade, New York Times
An engineer has invented a new technology for decoding DNA and used it to decode his own genome for less than $50,000.
In China, DNA tests on kids ID genetic gifts, careers
by Emily Chang, CNN
Parents are genetically testing their children for a range of potential skills and talents.
Pay donors to end the shortage of IVF eggs, says UK watchdog
by Mark Henderson, The Times (UK)
A longstanding ban on selling sperm and eggs should be reconsidered to address a national shortage of donors, the head of the UK Government's fertility watchdog says.
Dog Cloning Center to Open Next Year
by Kim Tong-hyung, Korea Times

A South Korea-based biotech firm plans to open a research center for canine cloning early next year.

Geron: FDA delays 1st trial of stem cell treatment
Associated Press
Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer Geron said.


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760